Back to Search
Start Over
Reversal of novel oral anticoagulants.
- Source :
-
Current Opinion in Pharmacology . Apr2016, Vol. 27, p86-91. 6p. - Publication Year :
- 2016
-
Abstract
- The development of a new generation of non-vitamin K oral anticoagulants represents a potential breakthrough in the management of patients with thrombotic diseases, disorders and conditions. While a large and growing body of evidence from large-scale clinical trials and registries supports a favorable safety profile, having a means to rapidly reverse their anticoagulant effects represents an unmet need among practicing clinicians. Several targeted reversal agents are currently in development and the early results are promising. Idarucizumab is a monoclonal antibody that can immediately and specifically reverse dabigatran. Andexanet alfa is a recombinant modified factor Xa that can bind and reverse oral and parenteral factor Xa inhibitors, including rivaroxaban, apixaban and edoxaban, and low molecular weight heparin. Aripazine is a small molecule that can reverse the action of factor Xa inhibitors and possibly dabigatran as well through non-covalent binding and charge–charge interactions. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14714892
- Volume :
- 27
- Database :
- Academic Search Index
- Journal :
- Current Opinion in Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 113953474
- Full Text :
- https://doi.org/10.1016/j.coph.2016.02.008